ZNTL

Zentalis Pharmaceuticals
$4.51
+$0.18 (+4.16%)Jul 27, 2026
2.9FairMoatMint rating

MoatMint rates Zentalis Pharmaceuticals (ZNTL) 2.9 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 3.2 out of 10.

Key metrics

The numbers that frame ZNTL today
Market cap
$321.05M
P/E (TTM)
-2.6
EV / FCF
-2.6
ROIC
-46.5%
Div yield
0%
Debt / equity
0.2
52wk Low
$1.21
52wk High
$6.95

ZNTL stock rating

How ZNTL scores on quality, value, growth, momentum and financial health
2.9out of 10
Fair overallFair business, expensive priceTop 71% of ~5,000 US stocks
QualityFair3.2/10
GrowthPoor1.1/10
MomentumGreat9.5/10
ValuePoor1.0/10
Financial HealthFair2.0/10

Growth

Revenue and earnings trend for ZNTL
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about ZNTL
Is Zentalis Pharmaceuticals a good buy?
Hold. Zentalis Pharmaceuticals has excellent momentum, but weak quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Zentalis Pharmaceuticals is selling at a very high price.
What is the market capitalization of ZNTL?
Zentalis Pharmaceuticals's market capitalization is $321.05M.
What is the P/E ratio for ZNTL stock?
Zentalis Pharmaceuticals's current P/E ratio is -2.6.
What is the 52-week high for ZNTL stock?
The 52-week high for Zentalis Pharmaceuticals is $6.95. The current close of $4.51 is 35.1% below that high.
What is the 52-week low for ZNTL stock?
The 52-week low for Zentalis Pharmaceuticals is $1.21. The current close of $4.51 is 272.1% above that low.
Does ZNTL stock pay dividends?
Zentalis Pharmaceuticals does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for ZNTL?
Zentalis Pharmaceuticals's Debt / Equity ratio is 0.19.